Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYTOMEL vs COLYTE WITH FLAVOR PACKS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.
Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.
Primary hypothyroidism (as replacement therapy),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Myxedema coma (off-label),Nontoxic goiter (off-label)
Bowel cleansing prior to colonoscopy or barium enema
Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.
Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.
The terminal elimination half-life of liothyronine is approximately 1.0-2.5 days in euthyroid individuals, but may be prolonged in hypothyroidism (up to 3-4 days) and shortened in hyperthyroidism. Clinical context: This short half-life allows rapid dose titration and withdrawal for thyroid suppression tests.
Not applicable (non-absorbed; no systemic absorption, thus no elimination half-life in plasma).
Primarily hepatic conjugation (glucuronidation and sulfation) and minor deiodination; not extensively metabolized by cytochrome P450.
Polyethylene glycol 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and metabolized normally.
Liothyronine (T3) is primarily eliminated by hepatic metabolism (deiodination and conjugation). Approximately 50-60% of a dose is excreted in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 20-30% via biliary elimination of conjugates.
Primarily fecal (100%) as non-absorbed oral solution; negligible renal or biliary elimination.
99.7% bound to plasma proteins, primarily thyroxine-binding globulin (TBG) (80%), transthyretin (10%), and albumin (10%).
Not applicable (non-absorbed; no systemic exposure).
Volume of distribution is approximately 0.4-0.6 L/kg, indicating distribution into total body water. Clinical meaning: Vd is lower than for T4 due to higher protein binding; rapid distribution into tissues occurs.
Not applicable (non-absorbed; no systemic distribution).
Oral bioavailability is approximately 95% (range 90-100%) when taken on an empty stomach; food may slightly reduce absorption. Intravenous bioavailability is 100%.
Oral: negligible systemic bioavailability (<0.1%) due to minimal absorption of polyethylene glycol and electrolytes.
No specific dose adjustment required for renal impairment.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment (GFR <30 m L/min) due to risk of fluid and electrolyte abnormalities.
No specific dose adjustment required for hepatic impairment; monitor thyroid function closely.
No specific dose adjustment for hepatic impairment; use standard dosing with caution in severe liver disease due to potential fluid shifts.
Initial 5 mcg orally once daily; increase by 5 mcg every 2-4 weeks based on thyroid function and clinical response. Maintenance: 25-50 mcg once daily. Weight-based: 1.6-2.6 mcg/kg/day.
Pediatric patients: 25-40 m L/kg/hour until rectal effluent is clear; maximum 4 liters total. Safety and efficacy not established for children under 6 months.
Start with lower initial dose of 12.5-25 mcg orally once daily; titrate slowly (increase by 12.5 mcg every 2-4 weeks) due to increased sensitivity and higher risk of cardiac complications. Monitor TSH closely.
Elderly: Consider reduced volume (e.g., 2-3 liters) and slower administration rate (e.g., 240 m L every 20 minutes) to mitigate risk of aspiration and electrolyte imbalance.
Not approved for weight loss; serious cardiovascular toxicity or death may occur, especially when used with sympathomimetic amines.
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES, SEIZURES, AND CARDIAC ARRHYTHMIAS. Use with caution in patients at risk for these conditions. Monitor fluid and electrolyte status.
Cardiovascular adverse effects (angina, arrhythmias, hypertension, myocardial infarction),Thyrotoxicosis from excessive dosing,May increase anticoagulant effect of warfarin,May reduce glycemic control in diabetes,Bone demineralization with prolonged use
Risk of aspiration, especially in patients with impaired gag reflex or reduced level of consciousness,Fluid and electrolyte disturbances (e.g., hyponatremia, hypokalemia) may occur; monitor in patients with renal or hepatic impairment, heart failure, or those taking diuretics or other drugs affecting electrolytes,Seizures and cardiac arrhythmias have been reported, often in patients with electrolyte imbalances or taking medications that lower seizure threshold,Mucosal ulcerations may occur; avoid use in patients with active inflammatory bowel disease or toxic megacolon,Arrhythmias (e.g., atrial fibrillation, QT prolongation) have been reported,Upper GI bleeding or obstruction; contraindicated in gastric retention or obstruction
Untreated thyrotoxicosis,Acute myocardial infarction,Uncorrected adrenal insufficiency
Gastrointestinal obstruction or ileus,Gastric retention or perforation,Bowel perforation,Toxic colitis or toxic megacolon,Hypersensitivity to any component
High-fiber foods, walnuts, soybean flour, and cottonseed meal may reduce absorption. Avoid excessive intake of iodine-rich foods (e.g., kelp, seaweed). Maintain consistent dietary habits for stable drug absorption.
Avoid all solid foods and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, black coffee, tea without milk, clear fruit juices without pulp, gelatin) are permitted. Do not consume red or purple liquids as they may be mistaken for blood during colonoscopy. Alcohol should be avoided for at least 24 hours prior to the procedure.
Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In first trimester, untreated maternal hypothyroidism linked to miscarriage and fetal anomalies; replacement therapy reduces risk. Second and third trimesters: maternal hypothyroidism associated with preterm birth, low birth weight, and impaired cognitive development; adequate dosing is critical. No evidence of teratogenicity at therapeutic doses.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte shifts could theoretically affect fetal fluid balance, but no known teratogenicity. First trimester: low risk based on lack of systemic absorption. Second/third trimester: theoretical risk of maternal electrolyte imbalance affecting fetal homeostasis, though no specific fetal adverse effects reported.
Liothyronine (T3) is excreted into human breast milk in low concentrations; M/P ratio not established. Exogenous T3 may suppress endogenous maternal thyroid function. Benefits of breastfeeding generally outweigh minimal risk; infant thyroid function should be monitored if mother requires high doses. Use with caution.
PEG is not absorbed systemically, thus minimal excretion into breast milk. M/P ratio not applicable/unknown. Considered compatible with breastfeeding as a bowel preparation, but caution with large volumes may alter maternal fluid/electrolyte status, indirectly affecting milk production or composition. Use only if clearly needed.
Pregnancy increases T3 clearance and decreases serum T3 levels. Dose requirements may increase by 30–50% compared to prepregnancy baseline. Frequent monitoring of free T3 and TSH is required; adjust dose to maintain free T3 in the upper normal range and TSH within trimester-specific targets. Dose adjustments should be made in increments of 5–12.5 mcg daily. Postpartum, dose usually returns to prepregnancy levels.
No specific pharmacokinetic changes in pregnancy requiring dose adjustment due to lack of systemic absorption. However, decreased gastrointestinal motility in pregnancy may prolong colonic transit time; no dose change recommended but monitor for tolerance. Use standard dosing (e.g., 4L in split dose) as in non-pregnant adults, with attention to hydration.
Initiate at low doses (5-12.5 mcg/day) in elderly or cardiac patients; increase gradually every 1-2 weeks. Monitor TSH, T3, and T4 levels; T3 therapy can cause rapid swings in thyroid hormone levels. Use with caution in adrenal insufficiency, coronary artery disease, or diabetes insipidus. May increase warfarin sensitivity; reduce anticoagulant dose. Discontinue 2-4 weeks before thyroid uptake scans.
Colyte with Flavor Packs is a polyethylene glycol 3350-based osmotic laxative used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after administration. Do not use flavor packs containing aspartame in patients with phenylketonuria. Monitor for electrolyte imbalances in patients with renal impairment or those on diuretics. Discontinue if severe bloating, abdominal pain, or vomiting occurs.
Take exactly as prescribed; do not change dose without consulting your doctor.,Take on an empty stomach, at least 30 minutes before food or other medications.,Notify your doctor if you experience chest pain, rapid heartbeat, nervousness, or excessive sweating.,Do not stop suddenly; abrupt withdrawal can cause hypothyroid symptoms.,Inform all healthcare providers you are taking this medication.,May increase sensitivity to blood thinners; report signs of bleeding.
Do not eat any solid food after starting the preparation; only clear liquids are allowed.,Mix the powder with water as directed and refrigerate to improve taste.,Drink the entire solution at the prescribed rate; set a timer if needed.,Expect watery stools; stay near a bathroom during the cleansing process.,Do not add extra flavorings or sweeteners unless provided in the pack.,Contact your doctor if you experience severe nausea, vomiting, or inability to keep the solution down.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYTOMEL vs COLYTE WITH FLAVOR PACKS, answered by our medical review team.
CYTOMEL is a Thyroid Hormone that works by Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.. COLYTE WITH FLAVOR PACKS is a Osmotic Laxative that works by Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYTOMEL and COLYTE WITH FLAVOR PACKS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYTOMEL is: Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.. The standard adult dose of COLYTE WITH FLAVOR PACKS is: Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYTOMEL and COLYTE WITH FLAVOR PACKS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYTOMEL is classified as Category C. Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In f. COLYTE WITH FLAVOR PACKS is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte sh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.